Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

@article{Park2011CosteffectivenessOL,
  title={Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.},
  author={Haesuk Park and Karen Rascati and Michael S Keith and Paul S. Hodgkins and Michael Smyth and David J. A. Goldsmith and Ron L. Akehurst},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2011},
  volume={14 8},
  pages={1002-9}
}
OBJECTIVE To assess the cost-effectiveness of lanthanum carbonate (LC) versus sevelamer hydrochloride (SH) as a treatment for hyperphosphatemia in end-stage renal disease (ESRD) patients. METHODS A Markov model was developed to estimate health outcomes; quality-adjusted life years (QALYs) and life-years saved (LYS), as well as associated costs. The model… CONTINUE READING